EDP Sciences logo
Open Access
Ann Toxicol Anal
Volume 22, Numéro 1, 2010
Page(s) 41 - 43
DOI https://doi.org/10.1051/ata/2010003
Publié en ligne 12 février 2010
  1. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology. 1993; 8(1): 23–33. [PubMed] [Google Scholar]
  2. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000; 40: 161–167. [CrossRef] [PubMed] [Google Scholar]
  3. VIDAL Expert (logiciel de consultation des bases VIDAL) ver.1.3.0-10250. VIDAL & Havas Medimedia, 2009. [Google Scholar]
  4. Baselt RC. Disposition of toxic drugs and chemicals in Man, 8th edn. Foster City: Biomedical Publications, 2008. [Google Scholar]
  5. Anderson D, Reed S, Lintemoot J, Kegler S, DeQuintana S, Sandlberg M, Muto J. A first look at duloxetine (Cymbalata®) in a postmortem laboratory. J Anal Toxicol. 2006; 30: 576–580. [PubMed] [Google Scholar]
  6. Waldschmitt C, Vogel F, Maurer C, Hiemke C. Measurement of duloxetine in blood using high performance liquid chromatography with spectrophotometric detection and column switch. Ther Drug Monit. 2007; 29(6): 767–772. [CrossRef] [PubMed] [Google Scholar]
  7. Lobo ED, Quinla T, O’Brien L, Knadler MP, Heatman M. Population pharmacokinetics of orally administered duloxetine in patients : implications for dosing recommandation. Clin Pharmacokinet. 2009; 48(3): 189–197. [CrossRef] [PubMed] [Google Scholar]
  8. Document consulté sur le site http://www.afssaps.fr le 01 juillet 2009. [Google Scholar]